Could a day-four model flag Kawasaki disease and complications earlier?
A Japanese hospital study separated 628 Kawasaki cases from 155 similar illnesses and predicted treatment resistance and aneurysm risk—but external and prospective validation are still missing.
The short version
- What happened
- Researchers analysed 628 children diagnosed with Kawasaki disease and 155 children with similar presentations, using LASSO logistic regression on history and laboratory data.
- Who it affects
- Families could benefit from faster escalation when Kawasaki disease is uncertain, but false reassurance or over-treatment would be serious.
- What remains unproven
- Single-hospital retrospective dataset
Keep in mind
Single-hospital retrospective dataset
No independent external or prospective validation
Discrimination does not prove calibration or better outcomes
Source analysis · 1 linked source. Primary analysed source date: 24 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 2 min The evidence, methods, implications and limitations
Three models addressed diagnosis, treatment response and aneurysm risk
A team at Fukuoka Tokushukai Hospital organised records by illness day and trained LASSO logistic-regression models using family and previous history plus laboratory measures such as neutrophils, bilirubin, C-reactive protein and AST. Optional inputs included BNP, IgG, fibrinogen and echocardiographic Z scores. The dataset contained 628 Kawasaki cases and 155 Kawasaki-like cases.
On day four, held-out test AUCs were 0.779 for Kawasaki diagnosis, 0.772 for resistance to intravenous immunoglobulin and 0.710 for aneurysm formation. On day five, the diagnosis model's positive predictive value exceeded 90%. Combining complication predictions identified 90% of complicated cases in the reported data.[1]
An application does not make the model clinically validated
Earlier support could matter because delayed treatment raises coronary-complication risk, and common clinical fields may be practical when optional tests are unavailable. The team implemented web and intranet versions, but deployment is not a trial of benefit.
The cohort came from one Japanese hospital. AUC also hides threshold trade-offs: services need to know how many children are missed and how many receive unnecessary escalation. External validation, calibration, subgroup analysis and a prospective clinician-impact study are the next tests.[1]
The distinction that matters
What the tool predicts
The application presents three probabilities rather than one definitive diagnosis.
Diagnosis
Compare Kawasaki with similar presentations
Day-four AUC 0.779
Treatment
Estimate IVIG non-response
Day-four AUC 0.772
Aneurysm
Estimate coronary-complication risk
Day-four AUC 0.710
Watch the background, then check the evidence
Illustrative photo · not a video frame
The Royal Society · 44 min 28 sec · Background explainer
Is this the AI future we want? | The Royal Society
YouTube loads only when you choose; playback starts when you press play.
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Published 2026-07-01. Source checked 14 October 2026. Check captions on the publisher’s video page.
Check the healthcare evidencePhoto: Daniel Sone / National Cancer Institute / Unsplash · Licence
Continue the story
Read next
Continue exploring paediatrics: compare the finding and its evidence limits.
Can a childhood-pneumonia risk model travel between hospitals?
A retrospective model trained on 5,546 children reached AUCs of 0.774 and 0.807 in two external Chinese cohorts. Different baseline risks shifted calibration, so local adjustment—not simple copying—remains necessary.
Read the next reportExplore the full source and evidence record
What this means for people
- Families could benefit from faster escalation when Kawasaki disease is uncertain, but false reassurance or over-treatment would be serious.
Global context
The model was developed in Japan. Kawasaki prevalence, referral pathways and laboratory timing differ internationally.
What the evidence does not yet show
- Single-hospital retrospective dataset
- No independent external or prospective validation
- Discrimination does not prove calibration or better outcomes
What to watch next
- Independent multi-centre validation
- Threshold-specific false negatives and false positives
- Calibration across populations
- Prospective comparison with standard assessment
Living evidence record
Impact record IAI-153OLC3
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
25 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what Scientific Reports published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 25 October 2026
Research question, topics and regions
Whether illness-day-indexed clinical data can support earlier Kawasaki diagnosis and predict treatment resistance or coronary aneurysm
Topics: Paediatrics · Kawasaki disease · Clinical decision support · Risk prediction
Regions: Japan
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.